First‐in‐Class Selective HDAC6 Inhibitor (ACY‐1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma

LESSONS LEARNED: Oral selective HDAC6 inhibitors could allow for decreased toxicity compared to pan‐class inhibitors, and increased ease of use. ACY‐1215 is well tolerated and led to disease stabilization in 50% of patients treated on a twice‐daily dosing schedule. Rational drug combinations with AC...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Amengual, Jennifer E., Lue, Jennifer K., Ma, Helen, Lichtenstein, Renee, Shah, Bijal, Cremers, Serge, Jones, Simon, Sawas, Ahmed
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2021
Gaiak:
Clinical Trial Results
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930426/
https://ncbi.nlm.nih.gov/pubmed/33458921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13673
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak